low - Prescription dermatology products demonstrate relative recession resilience as chronic inflammatory skin conditions require ongoing treatment regardless of economic conditions. However, high out-of-pocket costs for branded dermatology drugs ($50-150 copays) create modest sensitivity to consumer discretionary spending. Patient abandonment rates may increase 5-10% during economic downturns when households prioritize spending. The company's growth is driven primarily by market share capture and new patient starts rather than GDP-linked demand.

Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, with biotech sector multiples contracting 20-30% when 10-year yields rise 100bps; (2) Increased cost of capital for future financing needs, though current $115M+ cash position provides 12-18 month runway. The company's negative cash flow profile makes it more sensitive to rate-driven multiple compression than profitable peers.

growth - The stock attracts growth-oriented biotech investors focused on commercial-stage dermatology opportunities with blockbuster potential. The 230% revenue growth, 90%+ gross margins, and 113% one-year return appeal to momentum investors willing to accept negative cash flow for market share capture. High institutional ownership from healthcare-focused funds (RTW Investments, Perceptive Advisors) indicates sophisticated biotech specialists. Not suitable for value or income investors given negative earnings, no dividend, and 10.3x price-to-sales valuation.